- Home
- WGS vs RNA Comparison
WGS vs RNA Comparison
Compare WGS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGS | RNA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WGS | RNA |
|---|---|---|
| Price | $134.17 | $72.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $138.13 | $69.26 |
| AVG Volume (30 Days) | 380.3K | ★ 2.3M |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $402,190,000.00 | $20,868,000.00 |
| Revenue This Year | $41.17 | $57.30 |
| Revenue Next Year | $23.53 | $28.41 |
| P/E Ratio | $1,856.53 | ★ N/A |
| Revenue Growth | 50.50 | ★ 106.27 |
| 52 Week Low | $55.17 | $21.51 |
| 52 Week High | $170.87 | $72.61 |
Technical Indicators
Market Signals| Indicator | WGS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 72.68 |
| Support Level | $133.00 | $71.99 |
| Resistance Level | $143.95 | $72.30 |
| Average True Range (ATR) | 6.96 | 0.28 |
| MACD | -2.89 | -0.36 |
| Stochastic Oscillator | 6.64 | 67.13 |
Price Performance
Historical ComparisonAbout WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.